Clinical Trial Update: Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of carboplatin and paclitaxel in metastatic castration-resistant prostate cancer was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-04-12